KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2023 - 2025)

Biocryst Pharmaceuticals' Cash & Equivalents history spans 9 years, with the latest figure at $89.7 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 42631.43% year-over-year to $89.7 million; the TTM value through Dec 2025 reached $89.7 million, up 42631.43%, while the annual FY2025 figure was $89.7 million, 42631.43% up from the prior year.
  • Cash & Equivalents reached $89.7 million in Q4 2025 per BCRX's latest filing, up from $579000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $150.9 million in Q3 2023 to a low of $210000.0 in Q4 2024.
  • Average Cash & Equivalents over 3 years is $41.0 million, with a median of $1.8 million recorded in 2024.
  • The largest YoY upside for Cash & Equivalents was 42631.43% in 2025 against a maximum downside of 99.4% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $1.8 million in 2023, then plummeted by 88.36% to $210000.0 in 2024, then soared by 42631.43% to $89.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Cash & Equivalents are $89.7 million (Q4 2025), $579000.0 (Q3 2025), and $492000.0 (Q2 2025).